206 related articles for article (PubMed ID: 22494490)
1. An overview of the mTOR pathway as a target in cancer therapy.
Gentzler RD; Altman JK; Platanias LC
Expert Opin Ther Targets; 2012 May; 16(5):481-9. PubMed ID: 22494490
[TBL] [Abstract][Full Text] [Related]
2. Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer.
Nelson V; Altman JK; Platanias LC
Expert Opin Investig Drugs; 2013 Jun; 22(6):715-22. PubMed ID: 23544840
[TBL] [Abstract][Full Text] [Related]
3. Current and future directions in mammalian target of rapamycin inhibitors development.
Fasolo A; Sessa C
Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
[TBL] [Abstract][Full Text] [Related]
4. The mTOR protein as a target in thyroid cancer.
Souza EC; Ferreira AC; Carvalho DP
Expert Opin Ther Targets; 2011 Sep; 15(9):1099-112. PubMed ID: 21702716
[TBL] [Abstract][Full Text] [Related]
5. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
6. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.
Khokhar NZ; Altman JK; Platanias LC
Curr Opin Oncol; 2011 Nov; 23(6):578-86. PubMed ID: 21892085
[TBL] [Abstract][Full Text] [Related]
7. Current phase II clinical data for ridaforolimus in cancer.
Spreafico A; Mackay HJ
Expert Opin Investig Drugs; 2013 Nov; 22(11):1485-93. PubMed ID: 23964772
[TBL] [Abstract][Full Text] [Related]
8. [mTOR inhibitor].
Muro K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside.
Vincenzi B; Napolitano A; D'Onofrio L; Frezza AM; Silletta M; Venditti O; Santini D; Tonini G
Expert Opin Investig Drugs; 2011 Dec; 20(12):1685-705. PubMed ID: 22010859
[TBL] [Abstract][Full Text] [Related]
10. mTOR inhibitors in cancer therapy.
Zaytseva YY; Valentino JD; Gulhati P; Evers BM
Cancer Lett; 2012 Jun; 319(1):1-7. PubMed ID: 22261336
[TBL] [Abstract][Full Text] [Related]
11. New phosphatidylinositol 3-kinase inhibitors for cancer.
Bowles DW; Jimeno A
Expert Opin Investig Drugs; 2011 Apr; 20(4):507-18. PubMed ID: 21395485
[TBL] [Abstract][Full Text] [Related]
12. Use of mTOR inhibitors in the treatment of malignancies.
Mohindra NA; Giles FJ; Platanias LC
Expert Opin Pharmacother; 2014 May; 15(7):979-90. PubMed ID: 24666371
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review.
Zask A; Verheijen JC; Richard DJ
Expert Opin Ther Pat; 2011 Jul; 21(7):1109-27. PubMed ID: 21591993
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy.
O'Regan R; Hawk NN
Expert Opin Ther Targets; 2011 Jul; 15(7):859-72. PubMed ID: 21476875
[TBL] [Abstract][Full Text] [Related]
15. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
16. [mTOR complexes -- molecular spiders in molecular networks].
Kopper L; Tímár J
Magy Onkol; 2011 Nov; 55(4):287-94. PubMed ID: 22128312
[TBL] [Abstract][Full Text] [Related]
17. Identification of two novel inhibitors of mTOR signaling pathway based on high content screening.
Yan J; Zhou H; Kong L; Zhang J; Zhao Q; Li Y
Cancer Chemother Pharmacol; 2013 Oct; 72(4):799-808. PubMed ID: 23934262
[TBL] [Abstract][Full Text] [Related]
18. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
Gibbons JJ; Abraham RT; Yu K
Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
[TBL] [Abstract][Full Text] [Related]
19. The promise of mTOR inhibitors in the treatment of colorectal cancer.
Kim DD; Eng C
Expert Opin Investig Drugs; 2012 Dec; 21(12):1775-88. PubMed ID: 22978346
[TBL] [Abstract][Full Text] [Related]
20. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.
Diaz-Padilla I; Duran I; Clarke BA; Oza AM
Cancer Treat Rev; 2012 Oct; 38(6):767-75. PubMed ID: 22381585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
